Dr. Jakubowiak Discusses the Toxicity Profile of Panobinostat in the PANORAMA Trial

Andrzej Jakubowiak, MD, PhD
Published: Tuesday, Jun 17, 2014

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.

Jakubowiak says ideally, researchers aim to create a drug or drug combination that is more active with less toxicity. In the PANORAMA trial, there was a higher proportion of GI toxicities in the panobinistat arm compared to the placebo arm. There was also a higher rate of thrombocytopenia and other hematological toxicities. However, all of the toxicities were mostly manageable and did not impact the outcome, Jakubowiak says.

More details are needed to get a better understanding of the toxicity profile of this combination in this setting, Jakubowiak says.

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.

Jakubowiak says ideally, researchers aim to create a drug or drug combination that is more active with less toxicity. In the PANORAMA trial, there was a higher proportion of GI toxicities in the panobinistat arm compared to the placebo arm. There was also a higher rate of thrombocytopenia and other hematological toxicities. However, all of the toxicities were mostly manageable and did not impact the outcome, Jakubowiak says.

More details are needed to get a better understanding of the toxicity profile of this combination in this setting, Jakubowiak says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x